Printer Friendly

ONCOR ACQUIRES EXCLUSIVE LICENSE FROM CHILDREN'S HOSPITAL OF PHILADELPHIA

 -- DNA Probes to Identify Individuals
 with Congenital Heart Malformations --
 GAITHERSBURG, Md., July 16 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR) has acquired an exclusive license from the Children's Hospital of Philadelphia for DNA probes which can identify individuals with congenital heart malformations that are due to an inherited abnormality of chromosome 22. Children's Hospital of Philadelphia serves as a Human Genome Center for chromosome 22.
 The complex disorders associated with these chromosome 22 abnormalities include DiGeorge syndrome, Velo-cardiofacial (Shprintzen's) syndrome and CHARGE association. The availability of these probes allows for the identification of individuals with congenital heart malformations whose offspring are at an increased risk for the same malformation.
 Stephen Turner, Oncor's chairman and CEO, stated: "The genetic deletions on chromosome 22 represent one of the first discoveries of specific chromosome regions that contain genes responsible for inherited cardiovascular disease. This represents the beginning of Oncor's building of a position in cardiovascular genetic tests to assess risk of an individual for the onset of specific cardiovascular diseases in their lifetime. This is an emerging area of business opportunity for the company."
 Dr. Beverly S. Emanuel, professor of Pediatrics and director of the Human Genome Center at The Children's Hospital of Philadelphia, said: "Discovery of the deleted region on chromosome 22 represents identification of one of the first specific chromosomal regions known to contain genes responsible for specific forms of inherited cardiovascular malformation. Thus, the biggest impact will be to ultimately help scientists begin to understand the function of the genes that cause heart defects." The Children's Hospital of Philadelphia, the nation's first children's hospital, continues to advance children's health through education and research.
 Oncor develops, manufactures and markets Human Genome-based test systems for use in the early detection and management of cancer and other genetic diseases.
 -0- 7/16/93
 /CONTACT: Robert Borchert, or Eileen English, both of Morgen-Walke Associates, 212-850-5600, for Oncor, Inc./
 (ONCR)


CO: Oncor, Inc., Children's Hospital of Philadelphia ST: Maryland IN: HEA SU: CON

LD -- NY003 -- 2319 07/16/93 08:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1993
Words:335
Previous Article:PICTURETEL CORPORATION ANNOUNCES SECOND QUARTER REVENUE INCREASE OF 30 PERCENT; UNIT SHIPMENTS INCREASE APPROXIMATELY 54 PERCENT FROM 1992
Next Article:TEXAS INSTRUMENTS ANNOUNCES RECORD PROFIT, REVENUES
Topics:


Related Articles
ONCOR SIGNS EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZATION OF p58 GENE, POTENTIAL SUPPRESSOR OF MALIGNANT MELANOMA AND OTHER TUMORS
ONCOR AND THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE IN AGREEMENT TO RESEARCH AND COMMERCIALIZE NEW CANCER GENES
ONCOR ACQUIRES EXCLUSIVE LICENSES FOR DNA PROBES TO DETECT THE TELOMERES OF HUMAN CHROMOSOMES
/C O R R E C T I O N -- ONCOR, INC./
ONCOR ACQUIRES EXCLUSIVE LICENSE FOR GENE TO IDENTIFY INDIVIDUALS AT RISK FOR DEVELOPING VASCULAR DISEASE
ONCOR LICENSES GENETIC TECHNOLOGY FOR THE EARLY DETECTION OF A COMMON TYPE OF COLON CANCER
ONCOR, INC. LICENSES FUNCTIONAL GENE ASSAY TECHNOLOGY FROM MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER
ONCOR AND ONCORMED TO COLLABORATE WITH THE CALIFORNIA PACIFIC MEDICAL CENTER RESEARCH INSTITUTE
THE UNIVERSITY OF CALIFORNIA AND VYSIS, INC. SUPPLEMENT PATENT INFRINGEMENT COMPLAINT AGAINST ONCOR, INC.
Tenet Fills Top Leadership Positions at Hahnemann and MCP Hospitals.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters